Spots Global Cancer Trial Database for Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Official Title: A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Study ID: NCT00719212
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
St Jude Heritage Healthcare, Fullerton, California, United States
Wilshire Oncology Medical Group Inc, La Verne, California, United States
LAC/USC Medical Center, Los Angeles, California, United States
University of Southern California/ Norris Comprehensive Cancer Center, Los Angeles, California, United States
Cedars Sinai Medical Center, Los Angeles, California, United States
UCLA, Los Angeles, California, United States
North Valley Hematology/ Oncology Medical Group, Northridge, California, United States
Ventura County Hematology Oncology Specialists, Oxnard, California, United States
Central Hematology Oncology Medical Group Inc., Pasadena, California, United States
University of Colorado, Aurora, Colorado, United States
University of Chicago, Chicago, Illinois, United States
Cancer Center of Kansas, Wichita, Kansas, United States
St Joseph Mercy Health System, Ann arbor, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Comprehensive Cancer Centre of Nevada, Henderson, Nevada, United States
Tom Baker Centre, Calgary, , Canada
Juravinski Cancer Center, Hamilton, , Canada
CHUM Hôpital Notre Dama, Montreal, , Canada
Jewish General Hospital, Montreal, , Canada
Centre Hospitalier Départemental Les Oudairies, La Roche Sur Yon, , France
Centre Léon Berard, Lyon, , France
Clinique Hartmann, Neuilly sur Seine, , France
Institut Curie, Paris, , France
Institut Gustave Roussy, Villejuif, , France
Charité Campus Benjamin Franklin, Berlin, , Germany
Universitatsklinikum Erlangen, Erlangen, , Germany
Universitatsklinikum Hamburg Eppendorf, Hamburg, , Germany
Cork University Hospital, Cork, , Ireland
Mater Misericordiae University Hospital, Dublin, , Ireland
Mater Private Hospital, Dublin, , Ireland
St Jame's Hospital, Dublin, , Ireland
Waterford Regional Hospital, Waterford, , Ireland
Kaplan Medical Center, Rehovot, , Israel
Hospital Universitario de Tenerife, La Laguna (Santa Cruz de Tenerife), , Spain
Hospital U 12 de Octubre, Madrid, , Spain
Hospital Universitario Virgen Macarena de Sevilla, Sevilla, , Spain
Contact Details
Name: Gottfried E Konecny, MD
Affiliation: University of California, Los Angeles
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
